Physician profile
Rafid Asfar
NPI 1639468747
$10,164.96
in general payments reported to CMS, 2019-2025
37 companies · $4,878 in 2025
The $4,878 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $527 · 2021: $1,249 · 2022: $495 · 2023: $720 · 2024: $2,172 · 2025: $4,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,691 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,690.59 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,970.45 | 2020-2025 | Otezla, Otezla, Evenity |
| Ucb, INC. | $1,429.19 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,144.67 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $714.49 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $681.98 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $591.13 | 2022-2025 | Ofev, Cyltezo, Jascayd |
| Glaxosmithkline, LLC. | $523.82 | 2019-2025 | Benlysta, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $489.05 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $423.29 | 2020-2025 | Orencia |
| Lilly USA, LLC | $420.95 | 2020-2025 | Taltz, Zepbound, Olumiant |
| Pfizer INC. | $269.48 | 2020-2025 | |
| Genentech USA, INC. | $245.36 | 2020-2025 | Actemra |
| Ani Pharmaceuticals, INC. | $180.62 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $149.38 | 2025 | Acthar |
| Si-Bone, INC. | $145.35 | 2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $84.81 | 2021-2024 | Lupkynis |
| Genzyme Corporation | $75.44 | 2020-2025 | |
| Antares Pharma, INC. | $61.72 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $59.18 | 2023 | Idacio |
| Radius Health, INC. | $51.67 | 2021-2022 | |
| Horizon Therapeutics Plc | $45.32 | 2022 | |
| Kyowa Kirin, INC. | $41.24 | 2025 | |
| Boston Scientific Corporation | $40.28 | 2023-2025 | Wavewriter Alpha Prime 16, Varithena Administration Pack |
| Bayer Healthcare Pharmaceuticals INC. | $39.94 | 2022-2023 | |
| Bioventus LLC | $36.29 | 2024 | Supartz Fx Sodium Hyaluronate, Durolane |
| Sanofi-Aventis U.S. LLC | $35.30 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $24.72 | 2025 | Opsumit, Uptravi |
| Tonix Medicines, INC. | $22.53 | 2025 | Tonmya |
| Almatica Pharma LLC | $22.15 | 2025 | Teriparatide |
| Ibsa Pharma INC. | $21.04 | 2025 | Tirosint, Flector, Licart |
| Scilex Pharmaceuticals INC. | $20.19 | 2024 | |
| Abbott Laboratories | $19.93 | 2022 | |
| Ascendis Pharma Endocrinology INC | $18.25 | 2025 | Yorvipath |
| Corcept Therapeutics | $17.34 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $16.67 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $16.30 | 2021 | |
| Tandem Diabetes Care, INC. | $15.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafid Asfar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.